What is the dose of atropine for treating bradycardia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: July 5, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

The recommended dose of atropine for treating bradycardia is 0.5 mg administered intravenously (IV) as an initial dose, which can be repeated every 3-5 minutes if the bradycardia persists, up to a maximum total dose of 3 mg. This dosage is based on the most recent and highest quality study available, which prioritizes morbidity, mortality, and quality of life as the outcome 1. When administering atropine, it should be given as a rapid IV push followed by a saline flush to ensure quick delivery to the central circulation. It's essential to monitor the patient's heart rate, blood pressure, and ECG continuously during treatment. Atropine works by blocking the parasympathetic nervous system's effects on the heart, specifically blocking acetylcholine at muscarinic receptors, which increases the heart rate by reducing vagal tone.

  • Key considerations for atropine administration include:
    • Monitoring for potential paradoxical effects, particularly at low doses (less than 0.5 mg in adults), which may cause further slowing of the heart rate 1.
    • Caution in patients with acute coronary ischemia or myocardial infarction, as increased heart rate may worsen ischemia or increase infarction size 1.
    • Limited effectiveness in bradycardia caused by high-degree heart blocks or in heart transplant patients due to denervation 1.
  • The dosage and administration guidelines are supported by multiple studies, including those published in prestigious journals such as Circulation and the Journal of the American College of Cardiology 1. However, the most recent and highest quality study, published in 2019, provides the most up-to-date guidance on atropine dosing for bradycardia 1.

From the FDA Drug Label

The usual dose of atropine sulfate is 0.4 to 0.6 mg. The dose of atropine for treating bradycardia is 0.4 to 0.6 mg 2.

  • The dose may be exceeded in certain cases, but 0.4 to 0.6 mg is the usual dose.
  • Note that the label does not provide specific dosing instructions for bradycardia, but this is the standard dose for adults.

From the Research

Atropine Dosing for Bradycardia

  • The dose of atropine for treating bradycardia is typically administered intravenously, with studies suggesting various dosing regimens 3, 4, 5, 6, 7.
  • According to the studies, the initial dose of atropine can range from 0.5 to 1.0 mg, with some studies using a dose of 0.6 mg 4, 5.
  • In some cases, the dose may be repeated, with a total cumulative dose not exceeding 2.5 mg over 2.5 hours 4.
  • A study published in 2022 reported a case where a patient received a single dose of 600 micrograms of IV atropine for symptomatic 2:1 heart block, which resulted in paradoxical worsening of bradycardia 3.
  • Another study from 1999 found that patients with hemodynamically unstable bradycardia or atrioventricular block (AVB) who received atropine in the prehospital setting had a response rate of 19.8% partial, 27.5% complete, 49.6% none, and 2.3% adverse 7.

Key Considerations

  • The efficacy of atropine in treating bradycardia and AVB can vary depending on the underlying condition and the patient's response to treatment 5, 7.
  • Atropine is generally recommended as a first-line therapy for unstable bradycardic patients, with escalation to other treatments such as IV adrenaline or isoprenaline and transcutaneous pacing if atropine is unsuccessful 3.
  • The use of atropine requires careful medical supervision due to the potential for adverse effects, particularly at higher doses or in patients with certain underlying conditions 4.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.